<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03784833</url>
  </required_header>
  <id_info>
    <org_study_id>BIOMS-HF</org_study_id>
    <nct_id>NCT03784833</nct_id>
  </id_info>
  <brief_title>A Registry Study of Biomarkers in Heart Failure</brief_title>
  <acronym>BIOMS-HF</acronym>
  <official_title>A Registry Study of Biomarkers in Heart Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Institute of Heart, Lung and Blood Vessel Diseases</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Tianjin Medical University Second Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Second Affiliated Hospital of Wenzhou Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing Luhe Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>China-Japan Friendship Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Beijing Institute of Heart, Lung and Blood Vessel Diseases</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The registry study aims to discover the prognostic value of bio-markers in heart failure&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to investigate the prognostic value of biomarkers in Heart&#xD;
      Failure.Patients with confirmed diagnosis of heart failure are enrolled.The primary outcome&#xD;
      is all-cause mortality based on the death certificates. The secondary outcome is readmission&#xD;
      for heart failure and all-cause mortality/readmission for heart failure according to the&#xD;
      patients' medical records.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 2016</start_date>
  <completion_date type="Anticipated">June 2024</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of death (all cause)</measure>
    <time_frame>2 years of follow-up</time_frame>
    <description>Number of death within 2 years of discharge</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of rehospitalizations for acute heart failure (HF)</measure>
    <time_frame>2 years of follow-up</time_frame>
    <description>Number of heart failure related hospitalization within 2 years of discharge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of death ( all cause) or readmission for heart failure</measure>
    <time_frame>2 years of follow-up</time_frame>
    <description>Number of Death or heart failure related hospitalization within 2 years of discharge</description>
  </secondary_outcome>
  <enrollment type="Anticipated">5000</enrollment>
  <condition>Cardiovascular Diseases</condition>
  <biospec_descr>
    <textblock>
      Blood Samples&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with heart failure accorrding to Inclusion and exclusion criteria.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age greater than or equal to 18 years at the time of admission to the hospital&#xD;
&#xD;
          -  With symptoms of new-onset or worsening heart failure&#xD;
&#xD;
          -  Received or is eligible to receive a principal hospital discharge diagnosis of HF&#xD;
&#xD;
          -  With signs and syndromes as follows: dyspnea at rest or with minimal exertion&#xD;
             (dyspnea, orthopnea, or edema)ï¼›Rales, peripheral edema, ascites, or pulmonary vascular&#xD;
             congestion on chest radiography.&#xD;
&#xD;
          -  Patients who received packed red blood cells, whole blood, or platelets less than 10&#xD;
             days before the blood sample was taken;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Have objective evidence of cardiac dysfunction documented either by plasma&#xD;
             concentrations of BNP and/or N-terminal pro-brain natriuretic peptide (NT-proBNP) &lt;35&#xD;
             pg/mL or &lt;125 pg/ml, respectively&#xD;
&#xD;
          -  Current known inability to follow instructions or comply with follow-up procedures.&#xD;
&#xD;
          -  Eligible patients without informed consent form&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Jie Du, Dr</last_name>
    <role>Study Director</role>
    <affiliation>The Key Laboratory of Remodeling-Related Cardiovascular Disease, Ministry of Education, Beijing Anzhen Hospital, Capital Medical University, Beijing Institute of Heart,Lung and Blood Vessel Diseases</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yuan Wang, Dr</last_name>
    <phone>13910161443</phone>
    <email>wangyuan980510@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Bingbing Ke, Dr</last_name>
    <phone>15510286857</phone>
    <email>1017120710@qq.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Beijing Anzhen Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100029</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yuan WANG, PhD</last_name>
      <phone>86-010-64456169</phone>
      <email>wangyuan980510@163.com</email>
    </contact>
    <investigator>
      <last_name>Jie DU, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>December 20, 2018</study_first_submitted>
  <study_first_submitted_qc>December 20, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 24, 2018</study_first_posted>
  <last_update_submitted>April 21, 2019</last_update_submitted>
  <last_update_submitted_qc>April 21, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 23, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>heart failure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Cardiovascular Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

